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Abstract
Background: Subjects with type 2 diabetes are at an increased risk of vascular complications. The use of carotid ultrasound
remains an attractive, non-invasive method to monitor atherosclerotic disease progression and/or response to treatment in
patients with type 2 diabetes, with intima-media thickness routinely used as the gold standard to detect pathology. However,
alternative measurements, such as plaque area or volume, may represent a potentially more powerful approach. Thus, the
objective of this study was to compare the traditional intima-media thickness measurement against the novel total plaque volume
measurement in analyzing carotid atherosclerosis development in individuals with type 2 diabetes.
Methods: The case-control study included 49 Oji-Cree adults with diabetes or impaired glucose tolerance, aged 21–69, and 49
sex- and age-matched normoglycemic subjects. At baseline, metabolic variables were measured, including body mass index, waist
circumference, total cholesterol:high density lipoprotein ratio, plasma triglycerides, plasma glucose, and serum insulin. Carotid
ultrasound measurements, 7 years later, assessed carotid arterial intima-media thickness and total plaque volume.
Results: At baseline, the two groups were well matched for smoking habits, hypertension, body mass index, and waist
circumference. Differences were noted in baseline measurements of total cholesterol:high density lipoprotein (P = 0.0006),
plasma triglycerides (P < 0.0001) and fasting glucose (P < 0.0001). After seven years, carotid ultrasound scans revealed that total
plaque volume measurements (P = 0.037), but not intima-media thickness measurements, were higher in subjects with diabetes/
impaired glucose tolerance compared to the normoglycemic controls. Correlation between intima-media thickness and total
plaque volume was moderate. Based on our study findings, to achieve power levels >0.70 when comparing intima-media
thickness measurements for diabetics versus non-diabetics, thousands of study subjects are required. For comparing total plaque
volume measurements, only hundreds of study subjects are required.
Conclusion: The development of atherosclerotic plaque is greater in subjects with diabetes/impaired glucose tolerance. Total
plaque volume appears to capture the atherosclerotic disease burden more effectively in subjects with type 2 diabetes, and
would be an appropriate outcome measure for studies aimed at changing the diabetic milieu.
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Background
Macrovascular disease is the predominant contributor to
morbidity and mortality in patients with type 2 diabetes
[1]. Non-invasive assessment of arterial morphology
using carotid ultrasound (US) represents an attractive tool
to monitor progression and/or response to treatment in
patients with type 2 diabetes. The traditional endpoint is
intima-media thickness (IMT). Recently, however, newer
measurements such as assessment of plaque area or vol-
ume represent a potentially more powerful approach,
since this evaluates all plaques in the carotid system, and
predicts clinical events somewhat more strongly than does
IMT [2]. Thus, the objective of this case-control study was
to compare the traditional IMT measurement versus the
novel total plaque volume (TPV) measurement in analyz-
ing carotid atherosclerosis development in individuals
with type 2 diabetes.
Methods
Study Sample
Study participants were from the Oji-Cree community of
Sandy Lake, Ontario, an isolated reserve located at the
55th parallel of latitude, in the subarctic boreal forest of
central Canada. Baseline demographic, clinical, and bio-
chemical attributes were gathered during the Sandy Lake
Health and Diabetes Project of 1993–1995, a prevalence
study of type 2 diabetes [3]. Seven hundred and twenty
eight members of this community (72% of the total pop-
ulation) aged 10 years and above, participated in the orig-
inal survey. In a follow-up study initiated in 2001 [4], 278
adults free of coronary heart disease had US assessment of
the carotid arteries. Of these, 161 had participated in the
original prevalence study and had baseline measure-
ments. For the current analysis, 49 subjects, 46 with type
2 diabetes and 3 with impaired glucose tolerance (IGT),
were selected and matched for sex and age (± 3 years) with
a normoglycemic control subject. Of the subjects with dia-
betes, 43.5% were receiving oral medication, and 4.4%
were receiving insulin. For simplicity, from this point for-
ward the 46 subjects with type 2 diabetes and 3 with IGT
will be referred to as the "diabetic" group. Signed
informed consent was obtained from all participants and
study approval was granted by both the Sandy Lake First
Nation Band Council and the institutional review boards
of the University of Toronto and the University of Western
Ontario.
Clinical and biochemical baseline analysis
Body weight, height, waist circumference, and blood pres-
sure were measured by standardized procedures [3].
Hypertensive individuals were defined as subjects having
either a blood pressure reading >140/90 mmHg or taking
anti-hypertensive medication. Measurements of fasting
blood analytes, including triglycerides, insulin, lipopro-
teins, and total cholesterol were performed as described
[3].
Ultrasound examination
All subjects were examined using an HDI 5000 scanner
equipped with Sono-CT compound imaging and a L12-5
transducer (Advanced Technology Laboratories, Bothell,
Washington) that had been flown to the community and
housed within the Diabetes Research Center. Common
carotid US images for all participants were gathered over a
4-week period and from this data, IMT, total plaque area
(TPA) and TPV measurements were determined. TPA was
strongly correlated with TPV in these subjects (r = 0.921,
P < 0.0001), and thus for simplicity, only TPV measure-
ments were compared against IMT.
IMT measurement
IMT was determined as previously described [5,6]. Briefly,
a single observer, blinded to subjects' vascular risk, meas-
ured combined thickness of intima and media of the far
wall of both common carotid arteries. Images were
recorded from an anterolateral longitudinal view. The still
images were analyzed using computerized edge-detection
software (Prowin™) [7]. Using a step-wise algorithm, con-
ditional sets of "edges" (consisting of lumen-intima and
media-adventitia echoes) were located within the image
and then tested for "edge strength", with the subsequent
deletion of weak edge points. Once all acceptable edge
points were identified, boundary gaps were filled by linear
interpolation. The distance between lumen-intima and
media-adventitia boundaries was then measured to calcu-
late IMT. Mean IMT was computed from 120 measure-
ments over a 10 mm span ending 5 mm proximal to the
transition between the common carotid and bulb regions.
Intra- and inter-operator coefficients of variation of 3.0
and 3.1%, respectively and intra- and inter-operator intra-
class correlations were both 0.97 [n = 50] (both P < 0.01).
TPV measurement
TPV was determined as previously described [5,6]. Briefly,
3D ultrasound images were acquired with a mechanical
linear scanning system and analyzed with L3Di visualiza-
tion software [Life Imaging Systems Inc., London,
Ontario]. Plaque volumes were measured using manual
planimetry: each 3D image was 'sliced' transversely at an
inter-slice distance of 1 mm, moving from one plaque
edge to the other. Plaque boundaries were traced using a
mouse driven cross-haired cursor. Slice areas were
summed and multiplied by inter-slice distance to calcu-
late plaque volume. For this analysis, TPV was defined as
the sum of all plaque volumes on one side between the
clavicle and angle of the jaw. Intra- and inter-observer reli-
ability were 0.94 [n = 40] and 0.93 [n = 40], respectively
(both P < 0.01).Cardiovascular Ultrasound 2005, 3:15 http://www.cardiovascularultrasound.com/content/3/1/15
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Statistical analysis
SAS version 8.2 (SAS Institute, Cary, NC) was used for all
statistical comparisons. Data are presented as means ± SE.
The distribution of BMI, plasma total cholesterol, triglyc-
erides, high density lipoprotein (HDL), and serum insu-
lin, were non-normal in this data set, and thus were
logarithmically transformed (natural log) and subjected
to analysis of normality. IMT and TPV were also normal-
ized using the inverse transformation of IMT and the
square root transformation of TPV. The transformed vari-
ables were used for parametric statistical analyses, but the
untransformed values are presented in Table 1. For con-
tinuous variables, differences between the groups were
tested by the Student's t test; categorical variables were
tested by γ 2 analysis. Statistical significance was taken at
nominal P < 0.05 for all comparisons. Correlation analy-
sis between IMT and TPV was performed using Pearson
correlation analysis.
Hypothetical sample sizes were calculated using the
online calculator for normal power calculations (normal
distribution 2-sample equal variances) found at the UCLA
Department of Statistics website [8]. This statistical tool
calculates the sample size for two-sided tests of hypothe-
ses on normal means, when the common population
standard deviation is known, using the following
formula:
where n1 and n2 are the sample sizes of the two groups, uα /
2 and uβ  are the lower limits of the cumulative standard
normal probability integrals, σ   is the known common
standard deviation, δ 0 is the least favourable non-negative
difference consistent with the test hypothesis, and δ 1 is dif-
ference in the population means [9].
Using the normalized transformed means from the case-
control study, the mean standard deviation as the com-
mon standard deviation (SD), and a significance level of
0.05, sample sizes were calculated. Transformed means
and standard deviations were 1.29 (diabetic) vs  1.33
(non-diabetic), SD 0.237, for IMT (inverse transforma-
tion), and 7.81 (diabetic) vs 4.94 (non-diabetic), SD 6.71,
for TPV (square root transformation). Power was tested at
0.70, 0.80 and 0.90.
Results
Clinical and biochemical attributes of Oji-Cree subjects at 
baseline
As presented in Table 1, at the initial time of screening, the
average age of the study participants was 40.3 ± 1.8 years
for subjects with diabetes, and 40.4 ± 1.8 years for the
control subjects. 53.1% were females. Subjects with diabe-
tes were relatively newly diagnosed, with an average
Table 1: Clinical and biochemical attributes of Oji-Cree at baseline and carotid measurements after 7 years
Diabetic subjects Non-diabetic subjects P-value
number/females 49/26 49/26
attributes at screening
age (years) 40.3 ± 1.8 40.4 ± 1.8 NS (0.96)
duration of diabetes (years) 2.20 ± 0.62 - -
current smokers (%) 18.4 10.2 NS (0.25)
hypertensive (%) 36.7 32.7 NS (0.67)
antihypertensive treatment (%) 16.3 8.2 NS (0.22)
body mass index (kg/m2) 29.6 ± 0.5 29.5 ± 0.6 NS (0.75)
waist circumference (cm) 101 ± 1.4 99.8 ± 1.5 NS (0.63)
TC:HDL ratio 4.95 ± 0.18 4.10 ± 0.17 0.0006
plasma triglycerides (mmol/L) 2.25 ± 0.14 1.53 ± 0.11 <0.0001
plasma glucose (mmol/L) 10.79 ± 0.63 5.53 ± 0.07 <0.0001
serum insulin (pmol/L) 157 ± 12 133 ± 9 NS (0.16)
time elapsed since screening (years) 7.34 ± 0.10 7.33 ± 0.10 NS (0.96)
mean IMT (µm) 795 ± 19 789 ± 26 NS (0.49)
mean TPV (mm3) 109.9 ± 23.0 64.0 ± 17.0 0.037
Data are means ± SE unless otherwise indicated.
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diabetes duration of 2.20 ± 0.62 years. Comparing the
baseline characteristics of the diabetic and non-diabetic
subjects, there was no significant difference in terms of
smoking, hypertension, body mass index (BMI), waist cir-
cumference, or serum insulin concentrations. However,
both TC:HDL ratio and plasma triglyceride and glucose
concentrations were elevated in the diabetic subjects (P =
0.0006, P < 0.0001, and P < 0.0001, respectively).
Carotid plaque measurements after 7 years
Following 7 years, mean IMT values were slightly elevated
for subjects with diabetes (795 ± 19 µm) vs non-diabetic
subjects (789 ± 26 µm), however the difference was not
significant (P = 0.49). Mean TPV measurements, however,
were significantly higher in subjects with diabetes (109.9
± 23.0 mm3 vs 64.0 ± 17.0 mm3, P = 0.037). The simple
Pearson correlation coefficient between untransformed
IMT and TPV was 0.524 (P  < 0.0001) (Figure 1); the
Correlation between carotid arterial total plaque volume (TPV) and intima-media thickness (IMT) Figure 1
Correlation between carotid arterial total plaque volume (TPV) and intima-media thickness (IMT). Subjects 
with type 2 diabetes or IGT are represented with black dots (n = 49), while non-diabetic control subjects are represented with 
white dots (n = 49). The Pearson correlation coefficient (r) = 0.524.Cardiovascular Ultrasound 2005, 3:15 http://www.cardiovascularultrasound.com/content/3/1/15
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simple Pearson correlation coefficient between trans-
formed values (1/IMT and square root of TPV) was
approximately the same (r = -0.556, P < 0.0001).
Comparison of sample sizes required for hypothetical 
studies
Using the mean IMT and TPV results from our case-con-
trol study as primary endpoints, we determined the sam-
ple sizes that would be required for a hypothetical study
to achieve a statistical power of 0.70, 0.80 and 0.90. As
shown in Table 2, to detect a 6 µm difference in IMT, a
total of 1202 subjects would be required for a 0.70 power
level, 1528 subjects for a 0.80 power level, and 2044 sub-
jects for a 0.90 power level. To detect a 45.9 mm3 differ-
ence in TPV, a total of 136 subjects would be required for
a 0.70 power level, 172 subjects for a 0.80 power level,
and 230 subjects for a 0.90 power level.
Discussion
We report: 1) elevated TPV for diabetic subjects vs non-
diabetic subjects following a 7 year period (P = 0.037); 2)
increased sensitivity of the TPV measurement in compari-
son to IMT measurements for diabetic subjects.
A previous study by Hunt et al., convincingly showed that
early atherogenesis is present before the onset of diabetes,
and thus is not solely dependent on the clinical manifes-
tation of diabetes [10], but rather, both conditions (diabe-
tes and cardiovascular disease) originate from a "common
soil" of pro-inflammatory and pro-atherogenic risk factors
[11]. Our study examined atherosclerosis burden after the
diagnosis of diabetes had been made and found that dia-
betic subjects had TPV measurements that were 1.7-fold
higher than non-diabetic subjects (P  = 0.037). Similar
observations have been made previously, such as in the
Insulin Resistance Atherosclerosis Study (n = ~1200),
where subjects with diabetes had increased carotid wall
thickness at baseline (~70 µm increase in common
carotid, ~130 µm increase in internal carotid) [12], and,
over a five year time period, had IMT progression rates
approximately twice as high as non-diabetic subjects (7.2
± 1.9 vs 3.8 ± 1.3 µm/year) [13]. The Bruneck Study (n =
826) found that type 2 diabetes was a strong independent
predictor (OR = 5.0, P  < 0.001) of US-determined,
advanced stenotic atherosclerosis, defined by >40% lume-
nal narrowing [14].
Significant differences were also noted in the lipid profile
of diabetic subjects vs  controls, with a greater TC:HDL
ratio and elevated triglycerides observed for those with
diabetes. Glucose intolerance has been previously
reported as an independent predictor of both triglycerides
and HDL cholesterol [15]. This worsening of lipids with
glucose intolerance may potentially explain the differ-
ences between the two groups in terms of plaque volume
progression.
While a significant difference was found for TPV, no sig-
nificant difference was found for IMT between diabetic
and non-diabetic subjects, although IMT tended to be
greater for diabetic subjects. The lack of a significant dif-
ference undoubtedly is related to the low number of sub-
jects, but it is apparent that it may also be due to the
relative insensitivity of carotid IMT as a surrogate marker
for atherosclerosis in patients with type 2 diabetes. The
potential increased sensitivity for TPV was reflected by our
finding of a significant difference for a relatively small
study sample. An important feature for enhanced sensitiv-
ity is found in the wider dynamic scale ranges for TPV
compared to IMT: ~90% of the IMT measurements fall
within a relatively narrow 0.55–1.0 mm range, whereas
~60% of TPV values fall within a range of 5–500 mm3.
Thus, the dynamic range of measurements varied by
~100-fold for TPV compared to ~2-fold for the IMT. Fur-
thermore, the quantity being measured (mm3 for TPV vs
mm for IMT) is much larger for TPV, so that in relation to
Table 2: Comparison of sample sizes required for hypothetical trials with mean IMT or TPV as primary endpoints
Endpoint Significance Level Power Ndiabetic Nnon-diabetic N total
IMT (inverse): 6 µm difference
0.05 0.70 601 601 1202
0.05 0.80 764 764 1528
0.05 0.90 1022 1022 2044
TPV (square root): 45.9 mm3 difference
0.05 0.70 68 68 136
0.05 0.80 86 86 172
0.05 0.90 115 115 230
Abbreviations: IMT, intima-media thickness; TPV, total plaque volumeCardiovascular Ultrasound 2005, 3:15 http://www.cardiovascularultrasound.com/content/3/1/15
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the resolution of the ultrasound method, TPV is much eas-
ier to quantify both accurately and reliably.
In designing studies it may be worthwhile to consider
using TPV in addition to the traditional IMT measure-
ment, as a primary endpoint, due to its potentially greater
sensitivity and discrimination, which may have the bene-
fit of greater statistical power, allowing for the use of a
small sample size. For example, to observe a significant
difference in IMT using values similar to those observed in
this case-control study, (ie. 6 µm difference in mean IMT)
(Table 2), thousands of subjects are required to achieve a
statistical power of even 0.70. In contrast, only a few hun-
dred subjects are required to observe a statistical power of
0.90 for the TPV difference seen in our study (45.9 mm3).
Performing studies with over a thousand subjects [10,13]
imposes limitations and difficulties, which could be min-
imized by using a more sensitive technique such as TPV
measurement. Studies on the effects of therapy on athero-
sclerosis using TPV as the outcome have already been
effectively carried out with much smaller sample sizes.
Ainsworth et al. [16] have shown significant differences
between active atorvastatin and placebo in 3 months, with
a sample size of only 20 per group.
IMT and TPV, however, are not interchangeable. The cor-
relation between IMT and TPV in this study, although sta-
tistically significant, was moderate (r<0.7) and, as has
been noted previously, these different US-derived meas-
ures of carotid artery morphology likely represent distinct
attributes of atherosclerosis [5]. IMT may reflect wall
hyperplasia or hypertrophy related to hypertension [17]
and TPV may reflect the later stages of plaque formation
and the total carotid disease burden in a subject [5]. This
may be more relevant for the disease process of diabetes.
It is also important to note that in our previous work [5]
IMT correlated better with hypertension and age, and as
blood pressure and age were balanced between the
groups, this might explain the lack of difference observed
here for IMT. It may be the case that IMT would capture
the atherosclerotic disease burden more effectively in
hypertensive diabetics, and would be a more appropriate
outcome measure for studies aimed at improving hyper-
tension in diabetics. These implications must be taken
into consideration when designing and analysing a study,
and more research is needed to provide a complete under-
standing of how these US measures fit into the pathophys-
iology of atherosclerotic disease.
Considering that by nature atherosclerotic plaque is not
evenly distributed along the arterial wall, it is logical to
develop methods that will attempt to quantify the total
plaque burden more accurately. With the relatively larger
volumes being measured for TPV assessment vs IMT or
plaque area measurements, there are the accompanying
benefits of more statistical power and less patients
required per study, and also the potential benefit of less
time required to observe significant differences between
study groups. However, at present, using TPV as an assess-
ment tool remains a labour-intensive task and has the
additional disadvantage of not yet being widely used and
standardized. Furthermore, in studies among children or
other very young subjects, ultrasound evaluation of the
arteries may be limited to IMT simply because plaque
would not yet be developed in most cases. However, some
plaque can be identified in most subjects above age 35 or
40 [2].
Conclusion
In conclusion, this case-control study showed signifi-
cantly greater carotid TPV measurements in subjects with
type 2 diabetes vs subjects without type 2 diabetes, after a
7-year period. This supports previous reports of increased
carotid ultrasound analytes for persons with type 2 diabe-
tes, but additionally, this study highlights the effective-
ness of TPV as a marker for atherosclerotic disease burden
in diabetes, and encourages the further use and develop-
ment of this robust measurement. Currently the determi-
nation of TPV requires labour-intensive manual tracing,
which has proven to be an accurate and reliable measure-
ment [18,19]. Semi-automated methods are now in devel-
opment. However, for TPV to be used as a universally
implemented research/clinical tool, further studies will be
needed to clarify the relationships among IMT, TPV and
perhaps coronary plaque volume measured by intravascu-
lar ultrasound.
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